Gene delivery to dendritic cells by orally administered recombinant Saccharomyces cerevisiae in mice

被引:25
作者
Kiflmariam, Meron G. [1 ]
Yang, Hanjiang [1 ]
Zhang, Zhiying [1 ]
机构
[1] Northwest A&F Univ, Shaanxi Key Lab Mol Biol Agr, Coll Anim Sci & Technol, Yangling 712100, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
DNA delivery; S; cerevisiae; Yeast; Oral; Immune response; YEAST-BASED IMMUNOTHERAPY; CROSS-PRESENTATION; VIRAL VECTORS; THERAPY; CANCER; RESPONSES; PROTEINS; KINETICS; MUTATION; MODEL;
D O I
10.1016/j.vaccine.2012.11.048
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
DNA vaccination has caught the attention of many for triggering humoral as well as cellular immune responses. And delivering DNA into the antigen presenting cells (APCs) in order to induce efficient immunoresponse has become the backbone of this field. It has been confirmed that Saccharomyces cerevisiae, though non-pathogenic, is being engulfed by the dendritic cells and macrophages and delivers not only proteins, but also DNA materials (already confirmed in vitro). In this research, S. cerevisiae is used to deliver green fluorescent protein (GFP) reporter gene controlled under cytomegalovirus (CMV) promoter in living organism (mice). The recombinant yeast, transfected with the plasmid containing the GFP gene, was heat killed and orally administered to mice. After 60 h of yeast administration, mice were sacrificed and intestine was separated, washed and frozen in liquid nitrogen. Tissues were cut at the size of 10 pm using Cryostat machine, and GFP expression was successfully detected under a fluorescence microscope. After 45 days Western blot was able to detect GFP antibody in the blood of mice. These results imply that S. cerevisiae, being non-pathogenic, cheap, and easy to culture could be a good candidate to deliver DNA materials to the immune cells for vaccination. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1360 / 1363
页数:4
相关论文
共 36 条
  • [1] Vaccines based on whole recombinant Saccharomyces cerevisiae cells
    Ardiani, Andressa
    Higgins, Jack P.
    Hodge, James W.
    [J]. FEMS YEAST RESEARCH, 2010, 10 (08) : 1060 - 1069
  • [2] Baban Chwanrow K, 2010, Bioeng Bugs, V1, P385, DOI 10.4161/bbug.1.6.13146
  • [3] BALLOU CE, 1970, J BIOL CHEM, V245, P1197
  • [4] Kinetics of particle uptake in the domes of Peyer's patches
    Beier, R
    Gebert, A
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1998, 275 (01): : G130 - G137
  • [5] Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells
    Bernstein, Michael B.
    Chakraborty, Mala
    Wansley, Elizabeth K.
    Guo, Zhimin
    Franzusoff, Alex
    Mostboeck, Sven
    Sabzevari, Helen
    Schlom, Jeffrey
    Flodge, James W.
    [J]. VACCINE, 2008, 26 (04) : 509 - 521
  • [6] Recombinant Saccharomyces cerevisiae expressing p450 in artificial digestive systems:: a model for biodetoxication in the human digestive environment
    Blanquet, S
    Meunier, JP
    Minekus, M
    Marol-Bonnin, S
    Alric, M
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2003, 69 (05) : 2884 - 2892
  • [7] The 'biodrug' concept: an innovative approach to therapy
    Blanquet, S
    Marol-Bonnin, S
    Beyssac, E
    Pompon, D
    Renaud, M
    Alric, M
    [J]. TRENDS IN BIOTECHNOLOGY, 2001, 19 (10) : 393 - 400
  • [8] Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations
    Boehm, Amanda L.
    Higgins, Jack
    Franzusoff, Alex
    Schlom, Jeffrey
    Hodge, James W.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (03) : 397 - 408
  • [9] Specific activation of CMV-primed human T lymphocytes by cytomegalovirus pp65 expressed in fission yeast
    Breinig, F
    Heintel, T
    Schumacher, A
    Meyerhans, A
    Schmitt, MJ
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2003, 38 (03): : 231 - 239
  • [10] Cusack James C Jr, 2002, Surg Oncol Clin N Am, V11, P497, DOI 10.1016/S1055-3207(02)00029-7